NCT04038619 2026-03-18
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
M.D. Anderson Cancer Center
Phase 1 Recruiting
Clinical Trials
500 trialsNCT06148038 2026-03-18
CBD for Breast Cancer Primary Tumors
Medical University of South Carolina
Phase 1 Not yet recruiting
NCT04119024 2026-03-17
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Phase 1 Recruiting
NCT03725436 2026-03-16
ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03742245 2026-03-16
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
The Methodist Hospital Research Institute
Phase 1 Active not recruiting
NCT04253561 2026-03-16
IPATHER
SOLTI Breast Cancer Research Group
Phase 1 Completed
NCT06332508 2026-03-13
Pulsed Electromagnetic Fields (PEMFs) - A Highly Selective Breast CAncer Treatment pLatform (PASCAL)
National University Hospital, Singapore
Phase 1 Completed
NCT06218303 2026-03-12
Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ
University of Pittsburgh
Phase 1 Recruiting
NCT07457541 2026-03-12
Molecular Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI
Tomsk National Research Medical Center of the Russian Academy of Sciences
Phase 1 Active not recruiting
NCT06229392 2026-03-11
A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer
Rush University Medical Center
Phase 1 Withdrawn
NCT07080463 2026-03-10
VascuLens RCT
University of British Columbia
Phase 1 Enrolling by invitation
NCT07454668 2026-03-06
Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases
Baptist Health South Florida
Phase 1 Not yet recruiting
NCT04144023 2026-03-05
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
Mayo Clinic
Phase 1 Recruiting
NCT06251544 2026-03-04
TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer
Baylor College of Medicine
Phase 1 Not yet recruiting
NCT04270149 2026-02-27
Cancer Peptides Plus GM-CSF and Adjuvant in Breast Cancer
Duke University
Phase 1 Active not recruiting
NCT03641755 2026-02-23
Olaparib + Sapacitabine in BRCA Mutant Breast Cancer
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT02063724 2026-02-20
Adjuvant
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02157051 2026-02-17
Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer
University of Washington
Phase 1 Active not recruiting
NCT02776436 2026-02-17
REDEX
Leiden University Medical Center
Phase 1 Completed
NCT07300475 2026-02-13
Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients
Washington University School of Medicine
Phase 1 Not yet recruiting
NCT07408856 2026-02-13
CAN1012 in OED, DCIS, and LCIS.
Providence Health & Services
Phase 1 Not yet recruiting
NCT06678269 2026-02-12
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT06999798 2026-02-12
An Optimized Ultrasound Twinkling Marker for the Imaging of Lymph Nodes in Patients With Clinically Node-Positive Breast Cancer, The UTMOST2 Trial
Mayo Clinic
Phase 1 Recruiting
NCT05412225 2026-02-11
A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT06623396 2026-02-11
A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT05082259 2026-02-10
ASTEROID
Institute of Cancer Research, United Kingdom
Phase 1 Recruiting
NCT03237572 2026-02-09
Breast-48
University of Virginia
Phase 1 Terminated
NCT07055854 2026-02-09
MAC
Oregon State University
Phase 1 Recruiting
NCT03740256 2026-02-06
VISTA
Baylor College of Medicine
Phase 1 Recruiting
NCT05504707 2026-02-05
DecipHER
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Recruiting
NCT07387445 2026-02-04
A Multi-site Pilot Trial of Time Restircted Eating During Chemotheraply for Breast Cancer.
University of Illinois at Chicago
Phase 1 Not yet recruiting
NCT06171607 2026-02-02
Contrast Enhanced Ultrasound Medical Imaging for Identifying Breast Masses
University of Southern California
Phase 1 Recruiting
NCT02999477 2026-01-29
A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT04481113 2026-01-29
Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer
OHSU Knight Cancer Institute
Phase 1 Completed
NCT02432963 2026-01-28
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
City of Hope Medical Center
Phase 1 Active not recruiting
NCT05340673 2026-01-28
Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer
City of Hope Medical Center
Phase 1 Active not recruiting
NCT05996107 2026-01-28
Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer
University of Michigan Rogel Cancer Center
Phase 1 Recruiting
NCT06966388 2026-01-27
Study to Evaluate the Feasibility of Twice Daily Use of Topical Azelaic Acid in Breast Cancer Patients Undergoing Radiation
Virginia Commonwealth University
Phase 1 Recruiting
NCT06324240 2026-01-26
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
Emory University
Phase 1 Recruiting
NCT03863457 2026-01-22
[18F]F-GLN
Abramson Cancer Center at Penn Medicine
Phase 1 Recruiting
NCT04340180 2026-01-22
Evaluating the Performance of AI in Evaluating Breast MRI Performed With Dose Reduction
University of Alabama at Birmingham
Phase 1 Completed
NCT04360941 2026-01-21
PAveMenT
Royal Marsden NHS Foundation Trust
Phase 1 Recruiting
NCT05633979 2026-01-20
Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT05989828 2026-01-14
A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer
University of Southern California
Phase 1 Suspended
NCT07341867 2026-01-14
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Dana-Farber Cancer Institute
Phase 1 Not yet recruiting
NCT02284919 2026-01-09
ISO-1Primary
University of Pennsylvania
Phase 1 Active not recruiting
NCT04521764 2026-01-08
A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer
Mayo Clinic
Phase 1 Recruiting
NCT05809752 2026-01-08
A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Recruiting
NCT04616248 2026-01-07
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
University of Southern California
Phase 1 Active not recruiting
NCT07300202 2025-12-23
CLINICAL RESEARCH PROTOCOL [A Phase I, Single-arm, Open-label, Dose-escalation Clinical Study to Evaluate the Safety and Tolerability of Orialpha (BD-C) in Healthy Adult Volunteers]
Oriplantee Company Limited
Phase 1 Completed